"says the clown that needs a little over $4 to break even on MSB"Another desperate misdirection from
@Sector. He mined my old MSB posts to find something to embarrass. Went way too deep. There are 2 more recent posts where I rejoice as one of the many who took advantage of the uneducated market's reaction to LVAD results and loaded up bigtime around $1.15. My average is now about half of the quoted $4. I'm in the green.
This clown's smile is not painted on.
@Doug Diamond I do not come here to bignote MSB, to claim "mine is bigger". Every one of my approx 7 posts here is to correct misinformation. If Sector had not come to MSB threads more than 2 dozen times last year I would never have heard of CYP. He is obviously insecure about the competition. Relax, there is no competition.
Everything I have written here about CYP is respectful. I admire the technology and hope it works. I will invest in CYP if it ever approaches commercial status. Good luck to CYP. If and when it develops a product that shows promise of FDA approval I'll happily and securely invest. If it really is competing with MSB then I'll have no problem choosing between them.
Many of the people who come to these threads are not experienced in biotech or even in investing at all. I believe it is important to correct misdirections such as claiming that because one share has increased several fold compared to one that has decreased, then that share is a superior investment. We invest on future prospects, not past performance. CYP's future is a distant prospect at present. I hope that changes.
I expect there will be further egregiously incorrect and critical posts about my contributions here. I believe I have made my point and won't be replying. Open minded readers can make up their own minds now.
